.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Fuji
Healthtrust
Medtronic
Dow
US Department of Justice
Queensland Health
Mallinckrodt
Argus Health
Moodys

Generated: December 18, 2017

DrugPatentWatch Database Preview

Pf Prism Cv Company Profile

« Back to Dashboard

What is the competitive landscape for PF PRISM CV, and when can generic versions of PF PRISM CV drugs launch?

PF PRISM CV has fourteen approved drugs.

There are forty US patents protecting PF PRISM CV drugs and there have been two Paragraph IV challenges on PF PRISM CV drugs in the past three years.

There are eight hundred and twenty-three patent family members on PF PRISM CV drugs in seventy-seven countries and sixty-six supplementary protection certificates in fifteen countries.

Summary for Pf Prism Cv

International Patents:823
US Patents:40
Tradenames:10
Ingredients:10
NDAs:14
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pf Prism CvXALKORIcrizotinibCAPSULE;ORAL202570-001Aug 26, 2011RXYesNo► Subscribe► SubscribeY► Subscribe
Pf Prism CvVFENDvoriconazoleTABLET;ORAL021266-001May 24, 2002ABRXYesNo► Subscribe► Subscribe► Subscribe
Pf Prism CvLYRICApregabalinCAPSULE;ORAL021446-008Dec 30, 2004RXYesYes► Subscribe► SubscribeYY► Subscribe
Pf Prism CvXELJANZtofacitinib citrateTABLET;ORAL203214-001Nov 6, 2012RXYesYes► Subscribe► SubscribeY► Subscribe
Pf Prism CvLYRICApregabalinCAPSULE;ORAL021446-004Dec 30, 2004RXYesNo► Subscribe► SubscribeY► Subscribe
Pf Prism CvBOSULIFbosutinib monohydrateTABLET;ORAL203341-002Sep 4, 2012RXYesNo► Subscribe► Subscribe► Subscribe
Pf Prism CvLYRICApregabalinCAPSULE;ORAL021446-004Dec 30, 2004RXYesNo► Subscribe► Subscribe► Subscribe
Pf Prism CvZMAXazithromycinFOR SUSPENSION, EXTENDED RELEASE;ORAL050797-001Jun 10, 2005RXYesYes► Subscribe► SubscribeY► Subscribe
Pf Prism CvINLYTAaxitinibTABLET;ORAL202324-002Jan 27, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Pf Prism CvTORISELtemsirolimusSOLUTION;INTRAVENOUS022088-001May 30, 2007RXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Pf Prism Cv

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pf Prism CvVFENDvoriconazoleFOR SUSPENSION;ORAL021630-001Dec 19, 2003► Subscribe► Subscribe
Pf Prism CvRAPAMUNEsirolimusTABLET;ORAL021110-001Aug 25, 2000► Subscribe► Subscribe
Pf Prism CvVFENDvoriconazoleFOR SUSPENSION;ORAL021630-001Dec 19, 2003► Subscribe► Subscribe
Pf Prism CvVFENDvoriconazoleINJECTABLE;IV (INFUSION)021267-001May 24, 2002► Subscribe► Subscribe
Pf Prism CvRAPAMUNEsirolimusSOLUTION;ORAL021083-001Sep 15, 1999► Subscribe► Subscribe
Pf Prism CvRAPAMUNEsirolimusTABLET;ORAL021110-001Aug 25, 2000► Subscribe► Subscribe
Pf Prism CvVFENDvoriconazoleTABLET;ORAL021266-002May 24, 2002► Subscribe► Subscribe
Pf Prism CvRAPAMUNEsirolimusTABLET;ORAL021110-002Aug 22, 2002► Subscribe► Subscribe
Pf Prism CvVFENDvoriconazoleFOR SUSPENSION;ORAL021630-001Dec 19, 2003► Subscribe► Subscribe
Pf Prism CvRAPAMUNEsirolimusTABLET;ORAL021110-001Aug 25, 2000► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for PF PRISM CV drugs

Drugname Dosage Strength Tradename Submissiondate
tofacitinibTablets5 mgXELJANZ11/7/2016
bosutinibTablets100mg and 500mgBOSULIF9/6/2016
temsirolimusInjection25 mg/mL, 1.8 mL vialTORISEL5/25/2011
voriconazoleOral Suspension40 mg/mLVFEND10/8/2010
sirolimusTablets0.5 mgRAPAMUNE8/25/2010
pregabalinOral Solution20 mg/mLLYRICA5/19/2010
sirolimusTablets1 mg and 2 mgRAPAMUNE12/17/2009
tigecyclineFor Injection50 mg per vialTYGACIL6/15/2009
pregabalinCapsules25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mgLYRICA12/30/2008
voriconazoleFor Injection200 mg/vialVFEND9/12/2008
voriconazoleTablets50 mg and 200 mgVFEND4/14/2008

Non-Orange Book Patents for Pf Prism Cv

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,842,699Pyrrolo[2,3-D]pyrimidine compounds► Subscribe
6,140,366 GABA and L-glutamic acid analogs for antiseizure treatment► Subscribe
6,525,096 GABA and L-glutamic acid analogs for antiseizure treatment► Subscribe
8,106,197Aminoheteroaryl compounds as protein kinase inhibitors► Subscribe
7,432,370Chiral salt resolution► Subscribe
6,627,754 Pyrrolo[2,3-d]pyrimidine compounds► Subscribe
7,803,805Cristalline 3-{(3R,4R)-4 methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}- -3-oxo-propionitrile mono citrate salt► Subscribe
6,342,529 GABA and L-glutamic acid analogs for antiseizure treatment► Subscribe
6,297,258 Substituted 3-cyanoquinolines► Subscribe
5,684,189 GABA and L-glutamic acid analogs for antiseizure treatment► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Pf Prism Cv Drugs

Country Document Number Estimated Expiration
Poland379984► Subscribe
South Korea20060033851► Subscribe
World Intellectual Property Organization (WIPO)9858677► Subscribe
Israel161914► Subscribe
Russian Federation2384331► Subscribe
Australia2003291245► Subscribe
Taiwan200300690► Subscribe
Latvia13038► Subscribe
Japan3878849► Subscribe
Denmark0758244► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Pf Prism Cv Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
155Luxembourg► SubscribePRODUCT NAME: CRIZOTINIB, EVENTUELLEMENT SOUS LA FORME D UN SEL, HYDRATE OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE
C/GB06/033United Kingdom► SubscribePRODUCT NAME: TIGECYCLINE
04C/022Belgium► SubscribePRODUCT NAME: PREGABALIN; REGISTRATION NO/DATE: EU/1/04/279/001 20040708
/2004Austria► SubscribePRODUCT NAME: PREGABALIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES; REGISTRATION NO/DATE: EU/1/04/279/001 - EU/1/04/279/025 20040706
8Finland► Subscribe
90008-9Sweden► SubscribePRODUCT NAME: CRIZOTINIB INKLUSIVE ETT FARMACEUTISKT GODTAGBART SALT, SOLVAT ELLER HYDRAT DAERAV; REG. NO/DATE: EU/1/12/793/001 20121023
C/GB02/031United Kingdom► SubscribePRODUCT NAME: VORICONAZOLE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/02/212/001-025 20020319
00348Netherlands► SubscribePRODUCT NAME: TEMSIROLIMUS, DESGEWENST IN DE VORM VAN EEN; REGISTRATION NO/DATE: EU/1/07/424/001 20071119
1786785/01Switzerland► SubscribePRODUCT NAME: CRIZOTINIB; REGISTRATION NO/DATE: SWISSMEDIC 62131 05.03.2012
2004017Lithuania► SubscribePRODUCT NAME: PREGABALINUM ((S)-3-(AMINOMETIL)-5-METILHEKSANO RûGðTIS)
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Chubb
Accenture
Johnson and Johnson
Farmers Insurance
Chinese Patent Office
Cipla
Harvard Business School
UBS
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot